ArcherDX
- Industry
- Biotechnology
- Founded Year
- 2013
- Headquarters
- Boulder, Colorado, United States
- Employee Count
- 45
Key People
- Jason Myers - Co-founder & CEO
- Todd Druley - Chief Medical Officer
- Brian Wright - Director of Corporate Development
- Kyle Lefkoff - Board Member
- Josh Stahl - Chief Scientific Officer
- Matthew Franklin - VP - Business Development
- Benjamin Carver - VP - General Counsel
- Karen Fritschen - VP - Human Resources
- Richard Sjogren - VP - Operations
- Sandra Close - VP - Regulatory Affairs
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with successful backgrounds in the MedTech industry.
The presence of multiple successful MedTech entrepreneurs in the leadership team suggests a strong foundation for strategic decision-making and industry navigation.
- Clinical Need
-
Aspect: Very Strong
Summary: ArcherDX addresses a critical need in personalized genomic medicine for cancer diagnostics.
The development of next-generation sequencing-based assays for gene fusion detection directly addresses the growing need for personalized and precise cancer diagnostics.
- Competition
-
Aspect: Very crowded + Strategics
Summary: The market for genomic diagnostics is highly competitive with numerous strategic players.
The presence of numerous competitors, including large strategic companies, increases the difficulty of establishing a unique position in the market.
- Technical Challenge
-
Aspect: Predictable
Summary: The technical challenges associated with ArcherDX's products are manageable and well-understood.
Utilizing known next-generation sequencing techniques and bioinformatics, the technical hurdles are predictable and can be effectively managed.
- Patent
-
Aspect: Strong
Summary: ArcherDX holds strong patents that protect its proprietary technologies.
Strong patents covering key technologies enhance the company's ability to defend its market position and deter competitors.
- Financing
-
Aspect: Well-funded
Summary: ArcherDX has secured substantial funding to support its operations and growth.
With significant investments from reputable firms, ArcherDX is financially equipped to advance its product offerings and market reach.
- Regulatory
-
Aspect: 510k/PMA
Summary: ArcherDX is pursuing regulatory approvals for its diagnostic products.
Achieving 510(k) or PMA approvals is essential for the commercialization of medical devices, and ArcherDX's progress in this area is a positive indicator.
Opportunity Rollup
- Odds of Success
- 3.7
- Peak Market Share
- 4.9
- Segment CAGR
- 1.9%
- Market Segment
- In Vitro Diagnostics
- Market Sub Segment
- Molecular Diagnostics
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.24 |
| 2 | 0.73 |
| 3 | 1.71 |
| 4 | 3.43 |
| 5 | 4.90 |
Key Takeaway
ArcherDX, with its experienced team and strong financial backing, is well-positioned to address the growing demand for personalized cancer diagnostics, despite facing a competitive and rapidly evolving market landscape.